Peer-reviewedCC BYJournal of clinical medicine
Recorded Adoption of SGLT2 Inhibitors from 2022 to 2025 Among Adults with an EHR-Defined HFrEF Phenotype at a Jordanian Public Hospital
- 1Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, , Amman 19328, Jordan; (T.B.A.-B.); (A.A.)
- 2Department of Pharmacy Practice, , P.O. Box 84428, Riyadh 11671, Saudi Arabia;
Related
- C-Reactive Protein-to-Albumin Ratio and Hospital-Recorded Mortality in Patients with ICD-10-Coded Acute Kidney Injury: A Retrospective Cohort Study
- Hospital market concentration and hospital adoption of artificial intelligence and machine learning.
- Joint associations of baseline heavy physical work and waist-to-height ratio with hospital-recorded intervertebral disc disorders: a UK Biobank cohort study
- Adoption, usage patterns, and perceptions of DeepSeek among medical interns: Evidence from a Chinese Teaching Hospital
- Beyond combination: sequencing priming modalities before immune checkpoint inhibitors to convert immunologically cold tumors toward an ICI-responsive phenotype
BibTeX
@article{albawalsah2026recorded,
title = {{Recorded Adoption of SGLT2 Inhibitors from 2022 to 2025 Among Adults with an EHR-Defined HFrEF Phenotype at a Jordanian Public Hospital}},
author = {Tala Bassam Al-Bawalsah and Anas Abed and Alhareth Ahmad and Sireen Abdul Rahim Shilbayeh},
journal = {Journal of clinical medicine},
year = {2026},
month = sep,
url = {https://europepmc.org/article/PMC/PMC13666281},
note = {CC BY},
}
RIS
TY - JOUR
TI - Recorded Adoption of SGLT2 Inhibitors from 2022 to 2025 Among Adults with an EHR-Defined HFrEF Phenotype at a Jordanian Public Hospital
AU - Tala Bassam Al-Bawalsah
AU - Anas Abed
AU - Alhareth Ahmad
AU - Sireen Abdul Rahim Shilbayeh
PY - 2026
DA - 2026/09/29
JO - Journal of clinical medicine
UR - https://europepmc.org/article/PMC/PMC13666281
SN - 2077-0383
ER -